22:53 , Apr 5, 2019 |  BC Extra  |  Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

Emmanuel Dulac is leaving his post as chief international strategy officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to become the new CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL), effective April 22. Dulac succeeds Adam Steensberg, the...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer; lung cancer Cell culture and mouse studies suggest inhibiting GSK3 could help treat KRAS-driven pancreatic, colon and lung cancers. Screening of a library of 304 kinase inhibitors in cell-based growth...
17:46 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02) was generally well tolerated with...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro , cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in...
13:53 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; melanoma Mouse studies suggest inhibiting GSK3 could help treat lymphoma and melanoma. In a mouse model of lymphoma, a GSK3 inhibitor tool compound decreased tumor growth and increased survival compared with no treatment,...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen dependent kinase 3 (GSK3); dyskerin pseudouridine synthase 1 (DKC1)

Other INDICATION: Dyskeratosis congenita Patient sample and cell culture studies suggest GSK3 inhibitors could help treat dyskeratosis congenita, which is caused by mutations in DKC1 or other genes that result in shortened telomeres, dysfunction in...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Tideglusib: Phase II started

AMO began a single-blind, placebo-controlled, U.K. Phase II trial to evaluate 400 and 1,000 mg oral tideglusib for 14 weeks in up to 16 patients ages 12-45. AMO licensed rights to tideglusib from Noscira. AMO...
07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22- LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels...
07:00 , Mar 14, 2016 |  BioCentury  |  Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3 β (GSK3B); microtubule-associated protein τ (tau; MAPT; FTDP-17)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and rodent studies identified an isonicotinamide-based GSK3β inhibitor that could help treat AD or other tauopathies. Chemical synthesis of isonicotinamide analogs and testing in competitive binding assays yielded...